text.skipToContent text.skipToNavigation

miRCURY LNA miRNA Family Power Inhibitors

For analyzing regulatory roles shared by highly related, co-expressed and functionally redundant miRNAs
  • Enable functional analysis of an entire miRNA family, instead of just individual family members
  • LNA design ensures that all miRNA family members are silenced with similar high efficacy, regardless of GC content
  • More than 40 predesigned inhibitors of miRNA families available
  • Allows discovery of novel miRNA functions that would not be revealed when analyzing individual family members

miRCURY LNA miRNA Family Power Inhibitors allow you to study regulatory roles shared by highly related, co-expressed and functionally redundant miRNAs. Such functions would not be revealed in analyses using inhibitors of individual family members. These antisense oligonucleotides have perfect sequence complementarity to their targets, and when introduced into cells, they sequester the target miRNA in highly stable heteroduplexes that prevent interaction with the normal cellular partners.

Please contact us for ordering and for further information, or email our Support Team directly.

Cat No./ID: 339160
miRCURY LNA miRNA Power Family Inhibitors
Predesigned sets of miRCURY LNA miRNA Inhibitors for miRNA families

miRCURY LNA miRNA Family Power Inhibitors are intended for molecular biology applications. These products are not intended for the diagnosis, prevention, or treatment of a disease.

Example of miRNA family inhibitor design.
Example of miRNA family inhibitor design. (A) miR-30 family: identification of a shared sequence unique for the miR-30 family (in bold). In this particular case it was possible to design one short, complementary inhibitor, miR-30 Family Inhibitor (FI), with high duplex melting temperature (Tm) that binds with high specificity to members of the miR-30 miRNA family. (B) miR-200 family: silencing of the miR-200 family cannot be achieved with a single inhibitor. However, the five family members can be addressed with three inhibitors. The miR-200 Family Inhibitor (FI)-2 is the result of an oligonucleotide synthesis with a mixed-base composition, giving rise to two oligonucleotides that differ at position 7 (from the 5’ end). M = A,C. Letters in color indicate positions in which the target sequence varies between family members.
The miR-30 family positively regulates hMADS cell adipocyte differentiation.
(A) Sub-confluent hMADS cells were transfected with one of anti-miR control (anti-neg), anti-miR 30, pre-miR control (pre-miR-neg), pre-miR-30a, or pre-miR-30d and were induced to undergo adipocyte differentiation 3 days later. Differentiation was assessed at the indicated time points (D4 or D10) by photomicrographic recording (top row) and Oil red O plus crystal violet counterstaining (lower row). (B) Assessment of adipogenesis by GPDH enzymatic activity. Results are means of three culture wells (24-well plates). Error bars represent mean ± standard error of the mean (N = 3). *P < 0.05. (C) Expression of adipogenesis-induced genes (CEBPb, PPARg and FABP4) by qPCR. The level of expression of each gene in control cells (anti-miR-neg or pre-miRneg) was taken as 1. From Zaragosi et al. Genome Biology 2011, 12:R64. Reprinted with permission from BioMed Central.
Discover unknown miRNA function
miRNA family members are often co-expressed, either from the same pri-miR transcript or from distinct but co-regulated loci. This suggests that miRNAs within a family may share a common regulatory function. Given their identical seed sequence, miRNA family members will have many mRNA targets in common, and they are therefore likely to be functionally redundant. Therefore, analysis of miRNA family function requires simultaneous inhibition of all or several family members.

The miRCURY LNA miRNA Family Power Inhibitors allow you to observe robust phenotypes that would be either absent or weakly presented if using inhibitors of individual miRNA family members (see figure The miR-30 family positively regulates hMADS cell adipocyte differentiation). This enables you to discover new, unknown miRNA functions that you may have deduced through careful analysis of miRNA target predictions, but have not been able to prove experimentally.
miRCURY LNA miRNA Family Power Inhibitors are specifically designed to silence entire families of miRNAs, rather than individual family members. Through careful design, we have developed special family inhibitors that knock down all family members, while retaining specificity for the targeted family (see figure Example of miRNA family inhibitor design). This is achieved through the following design criteria:
  • Sequence optimization: identification of a target sequence sufficiently short to be shared by family members and sufficiently long to define the family.   
  • Mixed-base synthesis: when target sequences differ at a single position, we use a mixture of two bases at the corresponding position during the synthesis of the antisense oligonucleotide. This allows us to generate two oligonucleotides in a single oligonucleotide synthesis reaction.
  • Mixture of inhibitors: when it is not possible to target a whole family using a single nucleotide synthesis, we provide a mixture of two or more inhibitors that make up the family inhibitor.
  • LNA optimization: family inhibitors are short 10–16mers, but enhanced LNA content ensures that they all have the same target affinity (Tm) as our individual miRCURY LNA miRNA inhibitors.
The miRCURY miRNA Family Power Inhibitors have phosphorothioate backbones for enhanced stability and potency. All 43 Family Power Inhibitors are also available in a library plate format (miRCURY LNA miRNA Inhibitor Libraries).

We have developed inhibitors for more than 40 human miRNA families that are conserved in mouse. miRCURY LNA miRNA Family Power Inhibitors have been designed only for miRNA families in which the design criteria described above provide an advantage over simply using a mixture of individual inhibitors of all miRNA family members.

We define miRNA families as highly related miRNAs that share an identical seed sequence (nucleotides 2–8). This is particularly important for target recognition, although the miR-200 family is one of the few exceptions to this rule.

Some very large, miRBase-defined miRNA families, such as the hsa-miR-506, hsa-miR-515 and hsa-miR-548 families, comprise miRNAs with similar sequences but with different seed sequences. These families are not represented in our miRCURY LNA miRNA Family Power Inhibitors.

Power Inhibitors are not recommended for use with cells or cell lines derived from muscle or the central nervous system (CNS). These cell types are known to be particularly sensitive to sequence-dependent toxicity of phosphorothioate-modified oligonucleotides.
miRCURY LNA miRNA Family Power Inhibitors are antisense oligonucleotides with perfect sequence complementarity to their targets. When introduced into cells, they sequester the target miRNA in highly stable heteroduplexes, effectively preventing the miRNA from hybridizing with its normal cellular interaction partners. The sequences of the oligonucleotides and their LNA spiking patterns have been carefully designed to achieve uniform high potency, regardless of the GC content of the target. The Tm is normalized to an optimal temperature, and the level of self-complementarity is kept to a minimum.

Following resuspension, miCURY LNA miRNA Family Power Inhibitors are introduced into cells with a transfection reagent or via electroporation. Phenotypic effects are at an appropriate time thereafter.
miRCURY LNA miRNA Inhibitors are primarily used miRNA functional studies by assessing the biological consequences of inhibiting miRNA activity. These effects can be assessed in a variety of ways, including using cellular assays to monitor cell proliferation, cell differentiation or apoptosis. The effects on gene expression can also be measured at the mRNA or protein level of putative miRNA targets.
fragment fix placeholder